AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?
The cytoprotective effects of MK-801 and NBQX, selective N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonists, respectively, were compared both singularly and in combination in models of transient severe forebrain and transient focal c...
Auteurs principaux: | Buchan, A, Lesiuk, H, Barnes, K, Li, H, Huang, Z, Smith, K, Xue, D |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
1993
|
Documents similaires
-
Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction.
par: Xue, D, et autres
Publié: (1994) -
DELAYED TREATMENT WITH AMPA BUT NOT NMDA GLUTAMATE ANTAGONISTS REDUCES NEOCORTICAL INFARCTION
par: Xue, D, et autres
Publié: (1992) -
POSTISCHEMIC TREATMENT WITH AMPA, BUT NOT NMDA, ANTAGONISTS PREVENTS CA1 NEURONAL INJURY
par: Li, H, et autres
Publié: (1992) -
The rise and fall of NMDA antagonists for ischemic stroke.
par: Hoyte, L, et autres
Publié: (2004) -
NMDA antagonists: their role in neuroprotection.
par: Small, D, et autres
Publié: (1997)